Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report)’s stock price rose 5.3% on Tuesday. The company traded as high as $110.26 and last traded at $110.6320. 831,811 shares traded hands during trading, a decline of 53% from the average session volume of 1,788,709 shares. The stock had previously closed at $105.04.
Analysts Set New Price Targets
A number of brokerages recently weighed in on TWST. Canaccord Genuity Group decreased their price objective on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating for the company in a report on Friday. Robert W. Baird decreased their price target on Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday. Barclays lowered their price target on Twist Bioscience from $215.00 to $130.00 and set an “overweight” rating on the stock in a report on Monday. Piper Sandler increased their price objective on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Finally, TD Cowen decreased their target price on Twist Bioscience from $190.00 to $137.00 and set a “buy” rating for the company in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $133.92.
Get Our Latest Stock Analysis on Twist Bioscience
Twist Bioscience Price Performance
The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company has a market cap of $7.03 billion, a P/E ratio of -53.60 and a beta of 2.25. The firm’s fifty day moving average is $149.83 and its two-hundred day moving average is $93.39.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The company had revenue of $126.64 million during the quarter, compared to analyst estimates of $123.55 million. Twist Bioscience’s revenue was up 26.7% on a year-over-year basis. As a group, analysts anticipate that Twist Bioscience Corporation will post -1.52 earnings per share for the current fiscal year.
Insider Activity at Twist Bioscience
In other Twist Bioscience news, CFO Adam Laponis sold 8,057 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the completion of the sale, the chief financial officer owned 100,576 shares in the company, valued at $18,996,794.88. This represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 9,514 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,797,004.32. Following the sale, the insider directly owned 63,789 shares in the company, valued at approximately $12,048,466.32. The trade was a 12.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 495,279 shares of company stock valued at $80,489,387. 3.08% of the stock is owned by insiders.
Institutional Investors Weigh In On Twist Bioscience
A number of large investors have recently bought and sold shares of TWST. Readystate Asset Management LP purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at about $557,000. Ausdal Financial Partners Inc. acquired a new stake in Twist Bioscience during the third quarter worth about $261,000. Goldman Sachs Group Inc. grew its holdings in Twist Bioscience by 21.7% during the third quarter. Goldman Sachs Group Inc. now owns 1,714,716 shares of the company’s stock worth $331,352,000 after acquiring an additional 306,298 shares during the period. WCG Wealth Advisors LLC purchased a new position in Twist Bioscience during the third quarter valued at approximately $324,000. Finally, Durable Capital Partners LP purchased a new position in Twist Bioscience during the third quarter valued at approximately $48,503,000.
About Twist Bioscience
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Featured Stories
- Five stocks we like better than Twist Bioscience
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
